Last reviewed · How we verify
Magnevist
At a glance
| Generic name | Magnevist |
|---|---|
| Also known as | Gadopentetate dimeglumine |
| Sponsor | Bracco Diagnostics, Inc |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer (NA)
- Imaging in MGUS, SMM and MM (PHASE2)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
- PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer (PHASE2)
- Validity of Parametric MRI Using VIRADS (NA)
- Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis (PHASE2)
- Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases (PHASE4)
- Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Magnevist CI brief — competitive landscape report
- Magnevist updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI